These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27978986)

  • 1. Pharmacological considerations for predicting PK/PD at the site of action for therapeutic proteins.
    Wang W; Zhou H
    Drug Discov Today Technol; 2016; 21-22():35-39. PubMed ID: 27978986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tools for predicting the PK/PD of therapeutic proteins.
    Diao L; Meibohm B
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1115-25. PubMed ID: 25936400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PK-PD modeling of protein drugs: implications in assay development.
    Roskos LK; Schneider A; Vainshtein I; Schwickart M; Lee R; Lu H; Faggioni R; Liang M
    Bioanalysis; 2011 Mar; 3(6):659-75. PubMed ID: 21417734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.
    Ayyar VS; Jusko WJ
    Pharmacol Rev; 2020 Apr; 72(2):414-438. PubMed ID: 32123034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.
    Shah DK
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):553-71. PubMed ID: 26373957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    Yoon M; Kedderis GL; Yan GZ; Clewell HJ
    Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges.
    Schadt S; Hauri S; Lopes F; Edelmann MR; Staack RF; Villaseñor R; Kettenberger H; Roth AB; Schuler F; Richter WF; Funk C
    Drug Metab Dispos; 2019 Dec; 47(12):1443-1456. PubMed ID: 31748266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireview.
    Ing Lorenzini K; Daali Y; Dayer P; Desmeules J
    Basic Clin Pharmacol Toxicol; 2012 Mar; 110(3):219-26. PubMed ID: 21995512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of microdialysis for pharmacokinetic-pharmacodynamic modelling.
    Höcht C; Opezzo JA; Bramuglia GF; Taira CA
    Expert Opin Drug Discov; 2006 Sep; 1(4):289-301. PubMed ID: 23495900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology.
    Lees P; Giraudel J; Landoni MF; Toutain PL
    J Vet Pharmacol Ther; 2004 Dec; 27(6):491-502. PubMed ID: 15601443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety.
    Reichel A; Lienau P
    Handb Exp Pharmacol; 2016; 232():235-60. PubMed ID: 26330260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability.
    Chetty M; Rose RH; Abduljalil K; Patel N; Lu G; Cain T; Jamei M; Rostami-Hodjegan A
    Front Pharmacol; 2014; 5():258. PubMed ID: 25505415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling.
    Wu K; Li X; Zhou Z; Zhao Y; Su M; Cheng Z; Wu X; Huang Z; Jin X; Li J; Zhang M; Liu J; Liu B
    Front Pharmacol; 2024; 15():1330855. PubMed ID: 38434709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
    Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.
    Mori K; Saito R; Nakamaru Y; Shimizu M; Yamazaki H
    Biopharm Drug Dispos; 2016 Nov; 37(8):491-506. PubMed ID: 27604638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostics for confounding in PK/PD models for oxcarbazepine.
    Nedelman JR; Rubin DB; Sheiner LB
    Stat Med; 2007 Jan; 26(2):290-308. PubMed ID: 16615036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microdialysis for pharmacokinetic-pharmacodynamic studies.
    Yu W; Cheng Q; Feng J; Li F
    Pharmazie; 2007 Dec; 62(12):883-91. PubMed ID: 18214337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local kinetics and dynamics of xenobiotics.
    Pelkonen O; Kapitulnik J; Gundert-Remy U; Boobis AR; Stockis A
    Crit Rev Toxicol; 2008; 38(8):697-720. PubMed ID: 18686076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.